Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients

  • Park, Jeong A (Department of Pediatrics, Inje University Haeundae-Paik Hospital, Inje University College of Medicine)
  • 투고 : 2015.05.05
  • 심사 : 2015.07.07
  • 발행 : 2016.03.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or autoimmune disorders. The current treatment options, which include corticosteroids, transfusions, extracorporeal membrane oxygenation (ECMO), and immunosuppressants, have been limited and largely unsuccessful. Recombinant activated factor VII (rFVIIa) has been successfully administered, either systemically or bronchoscopically, to adults for the treatment of DAH, but there are few data on its use in pediatric patients. The current literature in the PubMed database was reviewed to evaluate the efficacy and risk of rFVIIa treatment for DAH in pediatric patients. This review discusses the diagnosis and treatment of DAH, as well as a new treatment paradigm that includes rFVIIa. Additionally, the risks and benefits of off-label use of rFVIIa in pediatric patients are discussed.

키워드

참고문헌

  1. Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med 2004;25:583-92. https://doi.org/10.1016/j.ccm.2004.04.007
  2. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010;137:1164-71. https://doi.org/10.1378/chest.08-2084
  3. Blatny J, Mathew P, Monagle P, Ovesna P, Fiamoli V. Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry. Blood Coagul Fibrinolysis 2014;25:326-32. https://doi.org/10.1097/MBC.0000000000000036
  4. Cetin H, Yalaz M, Akisu M, Karapinar DY, Kavakli K, Kultursay N. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant. Blood Coagul Fibrinolysis 2006;17:213-6. https://doi.org/10.1097/01.mbc.0000220245.20036.2d
  5. Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003;124:2400-3. https://doi.org/10.1016/S0012-3692(15)31709-8
  6. Heslet L, Nielsen JD, Levi M, Sengelov H, Johansson PI. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Crit Care 2006;10:R177. https://doi.org/10.1186/cc5132
  7. Henke D, Falk RJ, Gabriel DA. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 2004;140:493-4. https://doi.org/10.7326/0003-4819-140-6-200403160-00033
  8. Heslet L, Nielsen JD, Nepper-Christensen S. Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigm. Biologics 2012;6:37-46.
  9. Robbins RA, Linder J, Stahl MG, Thompson AB 3rd, Haire W, Kessinger A, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989;87:511-8. https://doi.org/10.1016/S0002-9343(89)80606-0
  10. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006;12:1038-46. https://doi.org/10.1016/j.bbmt.2006.06.002
  11. Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002;166:641-5. https://doi.org/10.1164/rccm.200112-141CC
  12. Newsome BR, Morales JE. Diffuse alveolar hemorrhage. South Med J 2011;104:269-74. https://doi.org/10.1097/SMJ.0b013e3182126d3b
  13. Park JA, Kim BJ. Intrapulmonary recombinant factor VIIa for diffuse alveolar hemorrhage in children. Pediatrics 2015;135:e216-20. https://doi.org/10.1542/peds.2014-1782
  14. Lee DS, Lee YI, Ahn JB, Kim MJ, Kim JH, Kim NH, et al. Massive pulmonary hemorrhage in enterovirus 71-infected hand, foot, and mouth disease. Korean J Pediatr 2015;58:112-5. https://doi.org/10.3345/kjp.2015.58.3.112
  15. Lee JY, Chon GR, Park JH, Kang BJ, Shim TS, Jo KW. Massive hemoptysis due to pulmonary vein stenosis following catheter ablation for atrial fibrillation. Respir Care 2015;60:e52-5. https://doi.org/10.4187/respcare.03336
  16. Fouret PJ, Touboul JL, Mayaud CM, Akoun GM, Roland J. Pulmonary Kaposi's sarcoma in patients with acquired immune deficiency syndrome: a clinicopathological study. Thorax 1987;42:262-8. https://doi.org/10.1136/thx.42.4.262
  17. Kim JS, Kim MJ, Bae EY, Jeong DC. Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome. Korean J Pediatr 2014;57:202-5. https://doi.org/10.3345/kjp.2014.57.4.202
  18. Krause ML, Cartin-Ceba R, Specks U, Peikert T. Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am 2012;32:587-600. https://doi.org/10.1016/j.iac.2012.08.001
  19. Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990;14:1112-25. https://doi.org/10.1097/00000478-199012000-00003
  20. Susarla SC, Fan LL. Diffuse alveolar hemorrhage syndromes in children. Curr Opin Pediatr 2007;19:314-20. https://doi.org/10.1097/MOP.0b013e3280dd8c4a
  21. Heggen J, West C, Olson E, Olson T, Teague G, Fortenberry J, et al. Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. Pediatrics 2002;109:965-71. https://doi.org/10.1542/peds.109.5.965
  22. Raptis A, Mavroudis D, Suffredini A, Molldrem J, Rhee FV, Childs R, et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999;24:879-83. https://doi.org/10.1038/sj.bmt.1701995
  23. Sindet-Pedersen S, Ramström G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989;320:840-3. https://doi.org/10.1056/NEJM198903303201305
  24. Taghaddomi RJ, Mirzaee A, Attar AS, Shirdel A. Tranexamic acid reduces blood loss in off-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2009;23:312-5. https://doi.org/10.1053/j.jvca.2008.09.018
  25. Solomonov A, Fruchter O, Zuckerman T, Brenner B, Yigla M. Pulmonary hemorrhage: a novel mode of therapy. Respir Med 2009;103:1196-200. https://doi.org/10.1016/j.rmed.2009.02.004
  26. Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 2010;125 Suppl 2:S51-4. https://doi.org/10.1016/S0049-3848(10)70013-X
  27. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 2010;14:R148. https://doi.org/10.1186/cc9216
  28. Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant 2006;12:949-53. https://doi.org/10.1016/j.bbmt.2006.05.012
  29. Rathi NK, Tanner AR, Dinh A, Dong W, Feng L, Ensor J, et al. Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage. Bone Marrow Transplant 2015;50:420-6. https://doi.org/10.1038/bmt.2014.287
  30. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996;26 Suppl 1:159-64.
  31. Al Hammadi AM, Sallah S. Efficacy and safety of recombinant factor VIIa in the treatment of bleeding episodes in patients with aplastic anemia. J Thromb Haemost 2007;5:435-6. https://doi.org/10.1111/j.1538-7836.2007.02353.x
  32. Farah RA, Hamod D, Melick N, Giansily-Blaizot M, Sallah S. Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency. J Thromb Haemost 2007;5:433-4. https://doi.org/10.1111/j.1538-7836.2007.02318.x
  33. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996;75:981-2.
  34. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879. https://doi.org/10.1016/S0140-6736(99)05155-7
  35. Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005;3:1935-44. https://doi.org/10.1111/j.1538-7836.2005.01523.x
  36. Yadav SP, Sachdeva A, Bhat S, Katewa S. Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion. Pediatr Hematol Oncol 2010;27:24-30. https://doi.org/10.3109/08880010903376988
  37. Harkensee C, Vasdev N, Gennery AR, Willetts IE, Taylor C. Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation: a systematic review and evidence-based guidance for clinical management. Br J Haematol 2008;142:717-31. https://doi.org/10.1111/j.1365-2141.2008.07254.x
  38. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012;3:CD005011.
  39. Brady KM, Easley RB, Tobias JD. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Paediatr Anaesth 2006;16:1042-6. https://doi.org/10.1111/j.1460-9592.2006.02039.x
  40. Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A. Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. Indian J Pediatr 2011;78:961-8. https://doi.org/10.1007/s12098-011-0364-6
  41. Esper RC, Estrada IE, de la Torre Leon T, Gutiérrez AO, Lopez JA. Treatment of diffuse alveolar hemorrhage secondary to lupus erythematosus with recombinant activated factor VII administered with a jet nebulizer. J Intensive Care 2014;2:47. https://doi.org/10.1186/s40560-014-0047-2
  42. Pathak V, Kuhn J, Gabriel D, Barrow J, Jennette JC, Henke DC. Use of activated factor VII in patients with diffuse alveolar hemorrhage: a 10 years institutional experience. Lung 2015;193: 375-9. https://doi.org/10.1007/s00408-015-9720-z
  43. Elinoff JM, Bagci U, Moriyama B, Dreiling JL, Foster B, Gormley NJ, et al. Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014;20:969-78. https://doi.org/10.1016/j.bbmt.2014.03.015
  44. Dabar G, Harmouche C, Jammal M. Efficacy of recombinant activated factor VII in diffuse alveolar haemorrhage. Rev Mal Respir 2011;28:106-11. https://doi.org/10.1016/j.rmr.2010.07.007
  45. Estella A, Jareno A, Perez-Bello Fontaina L. Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories. Cases J 2008;1:150. https://doi.org/10.1186/1757-1626-1-150
  46. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: a review. Crit Care Med 2006;34:871-7. https://doi.org/10.1097/01.CCM.0000201882.23917.B8
  47. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004;59:130-5. https://doi.org/10.1136/thorax.2003.013888
  48. Levi M, Schultz MJ, Rijneveld AW, van der Poll T. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003;31(4 Suppl):S238-42. https://doi.org/10.1097/01.CCM.0000057849.53689.65
  49. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791-800. https://doi.org/10.1056/NEJMoa1006221
  50. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007;(2): CD005011.
  51. Ellery PE, Adams MJ. Tissue factor pathway inhibitor: then and now. Semin Thromb Hemost 2014;40:881-6. https://doi.org/10.1055/s-0034-1395153
  52. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014;123:2934-43. https://doi.org/10.1182/blood-2013-11-512764
  53. Witmer CM, Huang YS, Lynch K, Raffini LJ, Shah SS. Off-label recombinant factor VIIa use and thrombosis in children: a multicenter cohort study. J Pediatr 2011;158:820-5.e1. https://doi.org/10.1016/j.jpeds.2010.10.038
  54. McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 2012;129:e1533-40. https://doi.org/10.1542/peds.2011-2561
  55. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion 2005;45:1434-42. https://doi.org/10.1111/j.1537-2995.2005.00548.x
  56. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8. https://doi.org/10.1001/jama.295.3.293
  57. Young G, Wicklund B, Neff P, Johnson C, Nugent DJ. Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children. Pediatr Blood Cancer 2009;53:179-83. https://doi.org/10.1002/pbc.22053
  58. Fekete M, Nemeth A. Neonatal pulmonary haemorrhage, birthweight, gestational age and intrauterine growth. Acta Paediatr Hung 1985;26:65-73.
  59. Larcombe PJ, Kapur N, Fraser CJ, Coulthard MG, Schlapbach LJ. Intrabronchial administration of activated recombinant factor VII in a young child with diffuse alveolar hemorrhage. Pediatr Blood Cancer 2014;61:570-1. https://doi.org/10.1002/pbc.24841
  60. Colin AA, Shafieian M, Andreansky M. Bronchoscopic instillation of activated recombinant factor VII to treat diffuse alveolar hemorrhage in a child. Pediatr Pulmonol 2010;45:411. https://doi.org/10.1002/ppul.21178
  61. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001;28:405-7. https://doi.org/10.1038/sj.bmt.1703157
  62. Veldman A, Fischer D, Voigt B, Beyer PA, Schlosser R, Allendorf A, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002;28:1635-7. https://doi.org/10.1007/s00134-002-1489-x
  63. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol 2002;22:672-4. https://doi.org/10.1038/sj.jp.7210787
  64. Leibovitch L, Kenet G, Mazor K, Matok I, Vardi A, Barzilay Z, et al. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med 2003;4:444-6. https://doi.org/10.1097/01.PCC.0000074276.20537.0A
  65. Grizelj R, Vukovic J, Filipovic-Grcic B, Saric D, Luetic T. Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. Blood Coagul Fibrinolysis 2006;17:413-5. https://doi.org/10.1097/01.mbc.0000233373.71970.6f

피인용 문헌

  1. Coagulation and Bleeding Management in Pediatric Extracorporeal Membrane Oxygenation: Clinical Scenarios and Review vol.5, pp.None, 2016, https://doi.org/10.3389/fmed.2018.00361
  2. Life-Threatening Pulmonary Hemorrhage Responds to Recombinant Factor VIIa: A Case Series in South Florida Hospitals vol.11, pp.11, 2016, https://doi.org/10.7759/cureus.6202
  3. Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis vol.22, pp.2, 2016, https://doi.org/10.3390/ijms22020793